(Q37566070)

21 August 2017

1 reference

title

Urine toxicology testing in chronic pain management (English)

1 reference

21 August 2017

0 references

0 references

Edward J Cone

1

1 reference

21 August 2017

Yale H Caplan

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

21 August 2017

published in

Postgraduate Medicine

1 reference

21 August 2017

volume

121

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

91-102

1 reference

Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

The management of persistent pain in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Primary care provider concerns about management of chronic pain in community clinic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Behavioral Monitoring and Urine Toxicology Testing in Patients Receiving Long-Term Opioid Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Urine drug screening in the medical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Detection time of drugs of abuse in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

A field evaluation of five on-site drug-testing devices

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Forensic drug testing for opiates. IV. Analytical sensitivity, specificity, and accuracy of commercial urine opiate immunoassays

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

The characterization of human urine for specimen validity determination in workplace drug testing: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Analysis of morphine and codeine in samples adulterated with Stealth

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Urine pH: the effects of time and temperature after collection

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Analytic performance of immunoassays for drugs of abuse below established cutoff values

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

The detection of hydromorphone in urine specimens with high morphine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Evidence that morphine is metabolized to hydromorphone but not to oxymorphone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Forensic drug testing for opiates. VII. Urinary excretion profile of intranasal (snorted) heroin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

The pharmacokinetics of heroin in patients with chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Identification of hydrocodone in human urine following controlled codeine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Role of urine toxicology testing in the management of chronic opioid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Methadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Alcoholism screening in patients with advanced cancer: impact on symptom burden and opioid use

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

ELISA detection of clonazepam and 7-aminoclonazepam in whole blood and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Interference by nonsteroidal anti-inflammatory drugs in EMIT and TDx assays for drugs of abuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

False-positive amphetamine screen following a trazodone overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Amphetamine positive toxicology screen secondary to bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Passive cannabis smoke exposure and oral fluid testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Consumption and quantitation of delta9-tetrahydrocannabinol in commercially available hemp seed oil products.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Ethyl glucuronide concentrations in two successive urinary voids from drinking drivers: relationship to creatinine content and blood and urine ethanol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Ethyl glucuronide--the direct ethanol metabolite on the threshold from science to routine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Evaluation of a new immunoassay for urinary ethyl glucuronide testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Methadone--metabolism, pharmacokinetics and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Long-term opioid contract use for chronic pain management in primary care practice. A five year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Development and validation of the Current Opioid Misuse Measure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Role of the primary care physician in problems of substance abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Rethinking confrontation in alcohol and drug treatment: consideration of the clinical context.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

The truth about pain management: the difference between a pain patient and an addicted patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

Abuse liability in opioid therapy for pain treatment in patients with an addiction history

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2035

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.07.2035

1 reference

21 August 2017

1 reference